Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

The Carlyle Group Inc. - Common Stock (NQ:CG)

45.95 +1.67 (+3.78%)
Streaming Delayed Price Updated: 3:30 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about The Carlyle Group Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Is Carlyle Group Gaining or Losing Market Support?
Via Benzinga
SoftBank Buys Silicon Valley Firm As It Goes All-In On AI
This is the third big AI move the bank has made this year. 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Masayoshi Son's SoftBank Buys Oracle-Backed Ampere For $6.5 Billion To Boost US AI Push
SoftBank has acquired Oracle-backed Ampere for $6.5 billion to strengthen its AI infrastructure strategy in the U.S., marking a major step in its broader push into Arm-based computing and large-scale... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Oppenheimer Analysts Slash Estimates For Goldman Sachs, Jefferies Amid Subdued M&A Activity
Analysts expect rebound in M&A and financing activity, but uncertainties may pause it. Estimates slashed for GS and JEF, CG downgraded to Perform. 
Via Benzinga
Tariffs Tangle Markets, Businesses, Investors
When uncertainty spikes, our ability to look out into the future shrinks. 
Via The Motley Fool
What's Driving the Market Sentiment Around Carlyle Group?
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
The Analyst Verdict: Carlyle Group In The Eyes Of 6 Experts
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout. 
Via Benzinga
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
Carlyle Group Stock Slips After Q4 Profit Miss: Retail Remains Neutral
The company’s fee-earning assets under management (AUM) fell by 1% to $304 billion compared with last year. 
Via Stocktwits
The Analyst Verdict: Carlyle Group In The Eyes Of 14 Experts
Via Benzinga
The Analyst Verdict: Carlyle Group In The Eyes Of 14 Experts
Via Benzinga
Advance Auto Parts Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Analyst Scoreboard: 12 Ratings For Carlyle Group
Via Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair
Industry experts join board of seasoned advisors offering strategic counsel on healthcare trends and policy for the company and its portfolio of state, federal, and commercial clients 
From Acentra Health
Via GlobeNewswire
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
From Vantive
Via GlobeNewswire
Acentra Health Appoints Ezmeralda Sager as Chief Transformation Officer
Industry changemaker to drive transformation and operational improvements in the development and delivery of the company’s healthcare products, solutions, and services 
From Acentra Health
Via GlobeNewswire
Copia Power and Arizona Public Service (APS) Enter Into 20-Year Power Purchase Agreements for Large-Scale Solar and Storage Energy Campus
Via ACCESS Newswire
2025 Industry Shake-Up: Goldman Highlights KKR, Raymond James, Hamilton Lane
Goldman Sachs predicts winners and losers among alternative asset managers, brokers, and traditional managers in 2025, with bold rating adjustments. 
Via Benzinga
Bank Of America Raises Bullish Outlook On US Brokers, Exchanges, Alternative Investments: 3 Top Picks For 2025
Bank of America bullish on U.S. brokers, asset managers and exchanges for 2025. Red wave in 2024 to open doors for crypto and alts. Blue Owl, IBKR and TW top picks; HOOD and SCHW underperformers. 
Via Benzinga
TeamViewer Agrees To Acquire Carlyle-Backed 1E For $720 Million: Details
TeamViewer to acquire 1E for $720 million, boosting IT performance and employee satisfaction. Deal expected to close in early 2025. 
Via Benzinga
Acentra Health’s Independent Medical Review Division Earns Accreditation from Leading Care Quality and Safety Organization
Consecutive accreditations from URAC spanning 24 years underscore the company’s unwavering compliance with rigorous standards for independent medical reviews 
From Acentra Health
Via GlobeNewswire
These 3 Stocks Are Heavy Hitters in Alternative Asset Management
These three companies are known for their expertise in alternative and private asset management, an industry with attractive characteristics. 
Via MarketBeat
Baxter International: Dividend Cut Because Of Restructuring
Baxter International (BAX) cut its dividend because of the upcoming sale of the Kidney Care business, high debt and leverage, lower earnings per share, and free cash flow. 
Via Talk Markets
Topics Stocks / Equities
Rubber Meets Road For Divergent Buyout-Shop Models
The share prices for the private equity and credit foursome, with nearly $3 trillion of combined assets under management, jumped immediately following the election. 
Via Talk Markets
9 Stocks To Watch: Financial Sector Outshines Tech In 2024 As 'Trump Trade' Sparks M&A Optimism
The Financial Select Sector SPDR Fund has surged 30% this year, outpacing the Technology Select Sector SPDR Fund. 
Via Benzinga
Trump Trade Sparks Biggest Financial Stock Inflows In 2 Years
Financial stocks rally after Trump's return to White House; investors expect deregulation and tax cuts. Goldman Sachs predicts top picks in sector. 
Via Benzinga
Topics Government
Exposures Political
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.